Unknown

Dataset Information

0

Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma.


ABSTRACT: Immune checkpoint inhibitors are effective for advanced hepatocellular carcinoma (HCC), but there remains a need for peripheral blood biomarkers to predict the clinical response. Here, we analyzed the peripheral blood of 45 patients with advanced HCC who underwent nivolumab. During treatment, frequency of classical monocytes (CD14+CD16-) was increased on day 7, and the fold increase in the frequency on day 7 over day 0 (cMonocyteD7/D0) was significantly higher in patients with durable clinical benefit (DCB) than in patients with non-DCB (NDB). When we analyzed transcriptomes of classical monocytes, CD274, gene encoding PD-L1, was upregulated in NDB patients compared to DCB patients at day 7. Notably, gene signature of suppressive tumor-associated macrophages, or IL4l1+PD-L1+IDO1+ macrophages, was enriched after treatment in NDB patients, but not in DCB patients. Accordingly, the fold increase in the frequency of PD-L1+ classical monocytes at day 7 over day 0 (cMonocyte-PDL1D7/D0) was higher in NDB patients than DCB patients. The combined biomarker cMonocyteD7/D0/cMonocyte-PDL1D7/D0 was termed the "monocyte index", which was significantly higher in DCB patients than NDB patients. Moreover, the monocyte index was an independent prognostic factor for survival. Overall, our results suggest that early changes of circulating classical monocytes, represented as a monocyte index, could predict clinical outcomes of advanced HCC patients undergoing anti-PD-1 therapy.

SUBMITTER: Jeon SH 

PROVIDER: S-EPMC9333050 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma.

Jeon Seung Hyuck SH   Lee Yong Joon YJ   Kim Hyung-Don HD   Nam Heejin H   Ryoo Baek-Yeol BY   Park Su-Hyung SH   Yoo Changhoon C   Shin Eui-Cheol EC  

Cancer immunology, immunotherapy : CII 20220728 2


Immune checkpoint inhibitors are effective for advanced hepatocellular carcinoma (HCC), but there remains a need for peripheral blood biomarkers to predict the clinical response. Here, we analyzed the peripheral blood of 45 patients with advanced HCC who underwent nivolumab. During treatment, frequency of classical monocytes (CD14<sup>+</sup>CD16<sup>-</sup>) was increased on day 7, and the fold increase in the frequency on day 7 over day 0 (cMonocyte<sub>D7/D0</sub>) was significantly higher in  ...[more]

Similar Datasets

2022-08-03 | GSE202145 | GEO
| PRJNA834794 | ENA
| S-EPMC11832464 | biostudies-literature
| S-EPMC9046782 | biostudies-literature
| S-EPMC10884244 | biostudies-literature
| S-EPMC4740301 | biostudies-literature
| S-EPMC9402369 | biostudies-literature
| S-EPMC6353899 | biostudies-literature
| S-EPMC7833759 | biostudies-literature
| S-EPMC7234956 | biostudies-literature